AbCellera Biologics Inc. (NYSE: ABCL) develops an antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Join the Community!: https://www.patreon.com/thenextmultibagger

00:00​ Intro 0:24​ Company Overview 10:24​ 2020 Financial Results 12:22​ Closing